Georg Pfeiler

6.3k total citations
91 papers, 1.7k citations indexed

About

Georg Pfeiler is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Georg Pfeiler has authored 91 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Oncology, 30 papers in Molecular Biology and 26 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Georg Pfeiler's work include Advanced Breast Cancer Therapies (20 papers), Breast Cancer Treatment Studies (18 papers) and Cancer Risks and Factors (15 papers). Georg Pfeiler is often cited by papers focused on Advanced Breast Cancer Therapies (20 papers), Breast Cancer Treatment Studies (18 papers) and Cancer Risks and Factors (15 papers). Georg Pfeiler collaborates with scholars based in Austria, Germany and United States. Georg Pfeiler's co-authors include Christian F. Singer, Robert Königsberg, Oliver Treeck, Olaf Ortmann, Michael Gnant, Michael Roden, Christian Dittrich, Attila Brehm, Robert Zeillinger and Giovanni Pacini and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Diabetes Care.

In The Last Decade

Georg Pfeiler

85 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Georg Pfeiler Austria	24	952	532	527	389	286	91	1.7k
Lu Li China	19	619 0.7×	766 1.4×	489 0.9×	156 0.4×	257 0.9×	73	1.8k
Yanyuan Wu United States	25	987 1.0×	1.3k 2.4×	635 1.2×	221 0.6×	314 1.1×	64	2.3k
Hiroshi Sonoo Japan	26	1.3k 1.4×	820 1.5×	645 1.2×	476 1.2×	292 1.0×	123	2.3k
Kathleen D. Whitney United States	16	695 0.7×	775 1.5×	318 0.6×	204 0.5×	135 0.5×	25	1.6k
Yasuo Hozumi Japan	23	964 1.0×	328 0.6×	704 1.3×	549 1.4×	522 1.8×	84	1.9k
Tonya C. Walser United States	23	840 0.9×	846 1.6×	423 0.8×	135 0.3×	407 1.4×	41	2.1k
Lisa M. Schumaker United States	24	702 0.7×	912 1.7×	346 0.7×	329 0.8×	264 0.9×	44	2.4k
Gary J. Smith United States	25	471 0.5×	785 1.5×	333 0.6×	214 0.6×	579 2.0×	74	1.8k
Lawrence A. Shirley United States	21	577 0.6×	525 1.0×	239 0.5×	121 0.3×	179 0.6×	48	1.5k
D. Lee Gorden United States	24	538 0.6×	623 1.2×	300 0.6×	197 0.5×	132 0.5×	38	1.9k

Countries citing papers authored by Georg Pfeiler

Since Specialization

Citations

This map shows the geographic impact of Georg Pfeiler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Georg Pfeiler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Georg Pfeiler more than expected).

Fields of papers citing papers by Georg Pfeiler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Georg Pfeiler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Georg Pfeiler. The network helps show where Georg Pfeiler may publish in the future.

Co-authorship network of co-authors of Georg Pfeiler

This figure shows the co-authorship network connecting the top 25 collaborators of Georg Pfeiler. A scholar is included among the top collaborators of Georg Pfeiler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Georg Pfeiler. Georg Pfeiler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Agostinetto, Elisa, Georg Pfeiler, Dominik Hlauschek, et al.. (2025). Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109). ESMO Open. 10(1). 104096–104096. 1 indexed citations

Wimmer, Kerstin, Dominik Hlauschek, Marija Balić, et al.. (2024). Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?. Breast Cancer Research and Treatment. 205(2). 227–239. 1 indexed citations

Bartsch, Rupert, Anna S. Berghoff, Julia Furtner, et al.. (2024). 187P Stage I results of a phase II study of datopotamab deruxtecan (DATO-DXd) in triple-negative breast cancer (TNBC) patients (pts) with active brain metastases (TUXEDO-2). ESMO Open. 9. 103209–103209. 4 indexed citations

Deutschmann, Christine, Christian F. Singer, Daphne Gschwantler‐Kaulich, et al.. (2023). Residual fibroglandular breast tissue after mastectomy is associated with an increased risk of a local recurrence or a new primary breast cancer". BMC Cancer. 23(1). 281–281. 6 indexed citations

Schmidt, Lukas, Martin Schreiber, Christine Pirker, et al.. (2023). Aberrant DNA Methylation, Expression, and Occurrence of Transcript Variants of the ABC Transporter ABCA7 in Breast Cancer. Cells. 12(11). 1462–1462. 6 indexed citations

Karch, Rudolf, et al.. (2022). Molecular dynamics identifies semi-rigid domains in the PD-1 checkpoint receptor bound to its natural ligand PD-L1. Frontiers in Bioengineering and Biotechnology. 10. 838129–838129. 2 indexed citations

Pirker, Christine, Martin Schreiber, Petra Heffeter, et al.. (2021). Discrimination between 34 of 36 Possible Combinations of Three C>T SNP Genotypes in the MGMT Promoter by High Resolution Melting Analysis Coupled with Pyrosequencing Using A Single Primer Set. International Journal of Molecular Sciences. 22(22). 12527–12527. 3 indexed citations

Falcone, Veronica, Elisabeth Reiser, Zsuzsanna Bagó-Horváth, et al.. (2021). Correlation Between Preoperative Radiological and Postoperative Pathological Tumor Size in Patients With HER2+ Breast Cancer After Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab. Clinical Breast Cancer. 22(2). 149–160.

Steger, Guenther G., Daniel Egle, Rupert Bartsch, et al.. (2020). Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT. The Breast. 50. 64–70. 13 indexed citations

10.

Mayer, Erica L., Angela DeMichele, Miguel Martín, et al.. (2020). LBA12 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer. Annals of Oncology. 31. S1145–S1145. 23 indexed citations

11.

Singer, CF, Daniel Egle, Richard Greil, et al.. (2020). 172P REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC). Annals of Oncology. 31. S77–S78. 1 indexed citations

12.

Nucíforo, Paolo, Dominik Hlauschek, Cristina Saura, et al.. (2019). Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial.. Journal of Clinical Oncology. 37(15_suppl). 1050–1050. 2 indexed citations

13.

Tea, Muy‐Kheng M., Yen Y. Tan, Ella Asseryanis, et al.. (2018). Improving comprehension of genetic counseling for hereditary breast and ovarian cancer clients with a visual tool. PLoS ONE. 13(7). e0200559–e0200559. 9 indexed citations

14.

Mayer, Erica L., Angela DeMichele, Georg Pfeiler, et al.. (2017). PALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer. Annals of Oncology. 28. v66–v66. 7 indexed citations

15.

Concin, Nicole, et al.. (2015). Prognostic Relevance of Pretherapeutic Gamma-Glutamyltransferase in Patients with Primary Metastatic Breast Cancer. PLoS ONE. 10(4). e0125317–e0125317. 47 indexed citations

16.

Pfeiler, Georg, et al.. (2015). Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer. Breast Cancer Research. 17(1). 125–125. 35 indexed citations

17.

Königsberg, Robert, Georg Pfeiler, Marcus Hudec, et al.. (2011). Prognostic Assessment and Adjuvant Treatment Strategies Within Early-Stage, Sporadic Triple Negative Breast Cancer Patients. Cancer Investigation. 29(2). 180–186. 5 indexed citations

18.

Königsberg, Robert, Eva Obermayr, Giovanna Bises, et al.. (2011). Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncologica. 50(5). 700–710. 206 indexed citations

19.

Pfeiler, Georg, Robert Königsberg, Thomas Geisendorfer, et al.. (2011). Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. Climacteric. 14(3). 339–344. 42 indexed citations

20.

Pfeiler, Georg, et al.. (2009). Correlation of body mass index and menopausal status with the intra-tumoral estrogen system in invasive breast cancer. Gynecological Endocrinology. 25(3). 183–187. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact